Ghosal hematodiaphyseal dysplasia

Ghosal hematodiaphyseal dysplasia (also known as Ghosal syndrome) is an extremely rare autosomal recessive disorder characterized by severe refractory anemia and diaphyseal dysplasia (abnormal thickening and sclerosis) of the tubular bones. The condition was first described by Ghosal and colleagues in 1988. It primarily affects the skeletal and hematopoietic (blood-forming) systems. The skeletal manifestations include marked cortical thickening and sclerosis of the diaphyses (shafts) of long bones, as well as sclerosis of the skull bones. The hematologic component presents as severe anemia that is typically refractory to standard treatments and may require repeated blood transfusions. The disease has been linked to mutations in the TBXAS1 gene (thromboxane A synthase 1), which plays a role in prostaglandin and thromboxane metabolism. Disruption of this pathway is thought to contribute to both the bone overgrowth and the impaired hematopoiesis observed in affected individuals. The condition typically presents in infancy or early childhood with progressive anemia and skeletal abnormalities. Additional features may include hepatosplenomegaly (enlargement of the liver and spleen) related to extramedullary hematopoiesis, as the body attempts to compensate for inadequate bone marrow function. Treatment is largely supportive and may include blood transfusions for anemia management. Corticosteroids have been reported to improve the anemia in some cases, possibly by modulating the prostaglandin pathway. Given the rarity of the condition, with only a handful of cases reported in the medical literature, there are no established standardized treatment guidelines, and management is individualized based on clinical presentation.

Common questions about Ghosal hematodiaphyseal dysplasia